4 ms·

The myocarditis connected to the vaccinations was reported to be almost always mild. And the higher risk for myocarditis compared to COVID (the topic of the lin

The myocarditis connected to the vaccinations was reported to be almost always mild. And the higher risk for myocarditis compared to COVID (the topic of the linked paper) only applies to the second shot of Moderna for people under 40, not for Biontech nor for people above 40. And this only compares myocarditis, COVID has other potential complications that were not within the scope of this paper. So it's reasonable to use Biontech instead of Moderna for young people, but the overall benefit of the vaccine still applies. The risks from COVID for young people are rare, but the side effect from the vaccine are even rarer.

gadflyinyoureye 5y ago
Again, do the added shots help with death and or hospitalization to such a degree that it’s worth the risk? Maybe I’m wrong, but from what I can see, given the age group of those involved in this particular population, the answer is no. They were already at low risks of death and or hospitalization. They were at low risk of complications from the disease itself. The benefit of the booster vaccine appears to be low in the population. Why risk it?
deleted 5y ago
[deleted]